Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSGALNACT1 | Q8TDX6 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004515 | 0.85 | MEN1 (0.55) | CSGALNACT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL214283 | 0.85 | MEN1 (0.49) | CSGALNACT1MEN1KMT2AALDH1A1GABRA5 | |
| SCHEMBL14019902 | 0.85 | SMN1; SMN2 (0.58) | CSGALNACT1MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL212148 | 0.83 | MEN1 (0.55) | CSGALNACT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18896197 | 0.82 | MEN1 (0.52) | CSGALNACT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20507158 | 0.81 | MEN1 (0.49) | CSGALNACT1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL212114 | 0.79 | NR4A1 (0.55) | CSGALNACT1MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL15464061 | 0.75 | MME (0.77) | — | |
| SCHEMBL16495932 | 0.74 | HPGDS (0.64) | GABRA5 | |
| SCHEMBL20162666 | 0.74 | SMN1; SMN2 (0.43) | MEN1KMT2AALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
| US-9663466-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CSGALNACT1 300/4885MEN1 2323/4885KMT2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.